COVAXIN

BIOLOGICAL2 trials

Sponsors

Bharat Biotech International Limited, Tan Tock Seng Hospital

Conditions

COVID-19SARS-CoV2 Infection

Phase 2

COVAXIN in a Pediatric Cohort

CompletedNCT04918797

Bharat Biotech International LimitedSARS-CoV2 Infection

Start: 2021-05-26End: 2022-01-25Updated: 2022-08-18

Phase 4

Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]

CompletedNCT05142319

Tan Tock Seng HospitalCOVID-19

Start: 2021-10-12End: 2024-05-07Updated: 2024-10-15

Related Papers

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial

Vaccine2024-09-05

Variant-Specific IgA Protects Against Omicron Infection.

2024-08-01

Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.

2022-06-1626 citations

Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].

2022-06-164 citations

Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial

Clinical Infectious Diseases2022-05-0442 citations